Biocatalist has unveiled a groundbreaking patented technology poised to transform the natural peptide industry by slashing manufacturing costs in this $40 billion market. What sets this technology apart is its unique ability to produce multiple peptide types from a single platform. Moreover, it offers several key benefits: up to 5-fold reduction in bioreactor size, leading to cost savings and a decreased environmental impact; the expansion of recombinant DNA technology to economically produce shorter natural peptides, eliminating toxic waste from chemical synthesis; and the cost-effective production of various peptides. Our innovation not only reduces production expenses but also supports Environmental, Social, and Corporate Governance (ESG) objectives for producers.